Published 4 days ago • loading... • Updated 3 days ago

GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients

GLP-1 receptor agonists may lower the risk of hematologic cancers in patients with type 2 diabetes according to a study published in JAMA Network Open.
The study found that GLP-1 receptor agonists were associated with a 54% lower risk of hematologic cancers compared to insulin.
A federal judge's ruling limits compounded GLP-1 access, threatening patient treatment options.
Dr. Taylor Kantor expressed concern that this ruling is a devastating setback for patients across the nation.

Insights by Ground AI

Does this summary seem wrong?

49 Articles

All

Left

Center

Right

STAT

As GLP-1 compounding stares down a wall, telehealth companies pivot to hormones

In the last two years, hundreds of businesses have cropped up to meet the surge in demand for the obesity and diabetes medications known as GLP-1s. The majority prescribe compounded copies of the drugs — a tenuous business strategy as shortages of the branded versions of the medications have come to an end. Now, some businesses are setting their sights on another opportunity in compounding: hormones. Dozens of wellness and direct-to-consumer t…

3 days ago·Boston, United States

Read Full Article

Rutland Herald

+45 Reposted by 45 other sources

Ivim Health Supports the Outsourcing Facilities Association's Appeal of Court Ruling That Further Restricts Access to Compounded GLP-1 Medications

Recent Federal Court Ruling Denying Request for an Injunction Will Endanger Patients by Limiting Access to Critical Weight Loss & Diabetes Drugs

3 days ago

Read Full Article

News Medical

GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 diabetes patients, especially compared to insulin. The study also highlights GLP-1RAs’ potential as a cancer-protective treatment, independent of glucose control.

4 days ago·United States

Read Full Article

Deutsches Ärzteblatt

GLP-1 agonists: Study finds no evidence of increased suicide risk – Deutsches Ärzteblatt

Montreal – Concerns that GLP-1 agonists, which are approved for the treatment of type 2 diabetes and obesity, increase the risk of suicide in patients have not been confirmed in an analysis of electronic medical records of British patients. According to the data published in the British Medical Journal (BMJ 2025; DOI:...

4 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year